27th Congress EAHP
March 2023

ABSTRACT NUMBER: 6ER-025

EFECTIVENESS AND SAFETY OF 20% AUTOLOGOUS SERUM EYE DROPS IN PATIENTS WITH CORNEAL SURFACE PATHOLOGIES

M. CANO ALONSO [1], A. PLANAS-GINER [1], N. ALMENDROS-ABAD [1], A.SOSA-PONS [1], L.CARDONA ROCA [1], L. CORONEL CORDERO [1], M. ROIG SORONELLAS [1] , N. RUDI SOLA [1].

[1] Pharmacy Department, Hospital General de Granollers, Granollers, Spain.

Correspondence: mcanoa@fphag.org

BACKGROUND AND IMPORTANCE

Autologous serum eye drops (SAED), a pharmaceutical formulation prepared from patient's blood, are used in corneal surface pathologies. Since alternative therapies are limited, its prescription has increased in recent years.

AIM AND OBJECTIVES

Analyse effectiveness and safety of SAED in patients diagnosed with corneal surface pathologies.

MATERIAL AND METHODS

Observational, retrospective study in a secondary hospital between Jan-2019 and Mar-2022.

Inclusion criteria: patients treated with 20% SAED.

Variables: demographic data, diagnose, concomitant diseases, duration of treatment, ocular affectation (left eye (LE), right eye (RE), both eyes (BE)), subjective clinical improvement (SCI)*, adverse effects (AE)*, concomitant treatments, visual acuity (VA)* at months 0, 3 and 6 of treatment.

Data was collected from electronic health record.

* Effectiveness was evaluated by SCI.
* VA was measured in decimal scale.
* Safety was evaluated by AE documented.

RESULTS

35 patients → 64% ♀, median 61 years (20-96).

DURATION

500 ± 348 days mean treatment length.

10 patients (28%) discontinued treatment.

CAUSES OF DISCONTINUATION (n; %)



- Reaction to 20% SAED
- Remission
- Death (not associated with treatment)
- Change of hospital

SUBJECTIVE CLINICAL IMPROVEMENT

SCI was observed in 82% patients at 3 and 6 months.

DIAGNOSES (n; %)



- Dry eye syndrome
- Superficial punctuate keratitis
- Sjögren syndrome
- Other diagnoses

PRINCIPALS ADVERSE EFFECTS

- Conjunctival hyperaemia (n=4)
- Blepharitis (n=2)
- Stinging (n=1)
- Tears with excess mucus (n=1)

OCULAR AFFECTATION

Twenty-nine patients (82%) had affection in both eyes.

VISUAL ACUITY EVOLUTION AT LE*



VISUAL ACUITY EVOLUTION AT RE*



* 14 patients (40%) data available.

CONCLUSIONS

According to SCI and VA's progressive improvement over the months and a low incidence of AE, 20% SAED are an effective and safe treatment for corneal surface pathologies.

ATC CODE: S03